CAR T-Cell Therapy in India — A 2026 Guide for Blood Cancer Patients from Africa

CAR T-cell therapy is the most significant advance in blood cancer treatment in a generation. For patients from Ethiopia, Uganda, Tanzania, and Gambia with relapsed or refractory blood cancers — leukaemia, aggressive lymphoma, multiple myeloma — who have exhausted standard treatments, it represents a category of option that did not meaningfully exist a few years ago.

India now has this therapy. It costs 70 to 80 percent less than in the United States or Europe. And for African patients who have been told there are no further options, it is worth understanding what it is, who qualifies, and what the treatment actually involves.

What CAR T-Cell Therapy Is

CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) is a form of personalised immunotherapy. The patient's own T cells — immune cells collected from their blood — are sent to a specialised laboratory where they are genetically modified. The modification adds chimeric antigen receptors (CARs) to the cell surface: artificial receptors that recognise and bind to a specific protein on the cancer cell's surface.

The modified cells are multiplied into the hundreds of millions and then reinfused into the patient. Once back in the body, these engineered T cells hunt down any cell expressing the target antigen, bind to it, activate, and kill it. They also multiply further in response to finding targets.

The responses in some patients have been dramatic. Overall response rates of 70 to 80 percent in relapsed or refractory large B-cell lymphoma and ALL patients who had failed multiple prior treatments. Complete remissions — no detectable cancer — in a significant proportion of responders. Some of these remissions are durable.

India's CAR T Programme — What Changed in 2026

India's development of indigenous CAR T-cell therapy marked a turning point. NexCAR19 — India's domestically developed CAR T therapy — has demonstrated a 70 percent overall response rate in clinical trials. Major centres including Amrita Hospital in Faridabad, BLK-Max in Delhi, and HCG in Bengaluru have treatment capacity of 500 to 750 patients annually.

The significance of domestic CAR T development is cost. Imported CAR T products from the United States cost USD 350,000 to USD 500,000. In India, CAR T-cell therapy ranges from USD 45,000 to USD 85,000 depending on the specific CAR T product, hospital infrastructure, patient's medical condition, and post-infusion care needs.

India reports approximately 120,000 new blood cancer cases annually. High-volume cancer centres in major cities including Delhi, Mumbai, Chennai and Hyderabad treat hundreds of thousands of oncology patients annually.

Who Qualifies for CAR T-Cell Therapy

CAR T-cell therapy is not first-line treatment. It is reserved for specific situations:

Large B-cell lymphoma — patients who have relapsed after or are refractory to two or more prior lines of therapy, including an anti-CD20 antibody and an anthracycline.

Acute Lymphoblastic Leukaemia (ALL) — relapsed or refractory B-cell ALL, particularly in younger patients. The CD19-targeting CAR T products (including NexCAR19) are most relevant here.

Multiple Myeloma — relapsed or refractory after four or more prior lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

Follicular Lymphoma — relapsed or refractory after two or more prior lines.

Before CAR T can proceed, patients must be fit enough to undergo the conditioning chemotherapy that precedes infusion, and must not have active uncontrolled infection or other conditions that would make the treatment too dangerous.

The CAR T Process — What It Involves

Leukapheresis: T cells are collected from the patient's blood through a process similar to blood donation but using a machine that separates the white blood cells. Takes three to four hours.

Manufacturing: The collected cells are sent to the laboratory, genetically modified, and multiplied. This takes approximately two to four weeks. During this period, patients may receive bridging therapy to control the disease while waiting.

Lymphodepleting conditioning: A course of chemotherapy given in the days before CAR T infusion. This reduces the patient's existing immune cells to make room for the incoming CAR T cells.

Infusion: The CAR T cells are given as an intravenous infusion, similar in appearance to a blood transfusion. Takes one to two hours.

Monitoring: The most critical period is the two to four weeks immediately following infusion. Cytokine release syndrome (CRS) — a potentially severe inflammatory response — occurs in many patients as the CAR T cells activate. Immune effector cell-associated neurotoxicity syndrome (ICANS) is another complication. Both require experienced oncology teams and ICU backup to manage.

Total time in India for CAR T-cell therapy: plan for eight to twelve weeks minimum.

Hospitals With CAR T Capability in Prime Medical's Network

CAR T-cell therapy requires specialised infrastructure — not every hospital offering oncology can administer it. Within hospitals accessible through Prime Medical:

Max Super Speciality Hospital (BLK-Max), Delhi — CAR T-cell therapy programme. Dr. Rohit Nayyar manages cancer care coordination. BLK-Max Delhi is specifically cited as one of India's centres with annual CAR T treatment capacity.

Indraprastha Apollo Hospital, New Delhi — Apollo's cancer programme includes CAR T capability. JCI accredited. Africa desk.

Amrita Hospital, Faridabad — Prime Medical partner. Amrita Hospital Faridabad is specifically listed as one of India's best affordable CAR T cell therapy centres in 2026.

Important Caveats for African Patients

CAR T is not bone marrow transplant. Some patients and families confuse the two. Both involve cell-based therapies but they are fundamentally different. Bone marrow transplant uses donor stem cells to replace the entire blood-forming system. CAR T uses the patient's own modified T cells to target a specific antigen.

Response is not guaranteed. 70 to 80 percent overall response rate means 20 to 30 percent of patients do not respond. The complete remission rate is lower than the overall response rate. Patients and families need honest conversations with the oncology team about realistic expectations.

Not a substitute for first-line treatment. CAR T is for patients who have already failed standard treatments. It is not a bypass of conventional treatment.

Starting the Process

Share haematology reports — bone marrow biopsy, flow cytometry, molecular testing, full treatment history — with Prime Medical Solutions. Dr. Rohit Nayyar at Max BLK reviews blood cancer cases and advises on whether CAR T-cell therapy is appropriate and which centre is most suitable.

To book a consultation, call the number on our website.